StimLabs Announces Enrollment of First Patient in CAMPSTIM Trial for Hard-to-Heal Diabetic Foot Ulcers
StimLabs, a leading regenerative medicine company, announced enrollment of the first patient in CAMPSTIM, a multi-center randomized controlled trial to demonstrate the clinical outcomes of StimLabs' placental-based tissue products with standard of care (SOC) compared to SOC alone, in patients with hard-to-heal diabetic foot ulcers (DFUs). This first patient was enrolled at Tulsa Wound Center by Dr. Lam Le.
StimLabs Announces IRB Approval for CAMPSTIM: The Largest Prospective Placental Tissue Allograft Trial for DFUs
StimLabs, a leading regenerative medicine company, announced Institutional Review Board (IRB) authorization to begin the CAMPSTIM clinical trial, a multi-center randomized controlled trial to demonstrate the real-world benefits of StimLabs’ placental-based tissue products in treating patients with hard-to-heal diabetic foot ulcers (DFUs).
StimLabs awarded Reconstructive Skin Grafting products agreement with Premier, Inc.
StimLabs, a pioneering regenerative medicine company, has been awarded a national group purchasing agreement in the Reconstructive Skin Grafting category with Premier, Inc. Effective April 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select StimLabs allografts.
FDA Clears Groundbreaking Corplex P: The First Human Umbilical Cord-Derived Medical Device
StimLabs announces FDA 510(k) clearance of Corplex P, the pioneering human umbilical cord-derived medical device. This first-of-its-kind clearance marks a significant milestone for the wound care industry and highlights StimLabs’ position at its forefront.
Stimlabs LLC Announces Two New Patents Further establishing the Company’s Intellectual Property Position for Advancements in Regenerative Medicine
Stimlabs LLC, (“StimLabs”), a leader in regenerative medicine, continues to achieve advancements in the development and patenting of innovative, industry-leading technologies and products.
Stimlabs LLC Announces Launch of Relese - A Uniquely Fenestrated Allograft for Chronic and Acute Wounds
/PRNewswire/ -- Stimlabs LLC, ("StimLabs"), a leader in regenerative medicine, announced the launch of Relese, a fenestrated dehydrated complete human placental membrane (dCHPM) allograft for chronic and acute wounds.
Revita Revolutionizes Patient Care
Revita for wound care, by StimLabs, is the first intact placental membrane allograft on the market.
Placental allograft, cytology processor, cell-free RNA testing, and male infertility
Human placental allograft Revita, an allograft composed of human placental membrane, developed by Stimlabs, is available to ObGyns and other health care professionals for many uses including surgery and wound care. The human placental membrane is compos...
StimLabs Announces Department of Veterans Affairs (VA) And Department of Defense (DoD) ...
/PRNewswire/ -- StimLabs, LLC, a leader in regenerative technologies and products that are revolutionizing patient care, is pleased to announce availability of...
StimLabs Announces Enrollment of First Patient in Evaluating Efficacy of Full Thickness...
/PRNewswire/ -- StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced that the first patient has...
StimLabs Announces Partnership with American Military Medical Organization, LLC
/PRNewswire/ -- StimLabs, LLC, a leader in regenerative technologies and products that are revolutionizing patient care, is pleased to announce a partnership...
StimLabs Enters Regenerative Medicine Market with Two Groundbreaking Amniotic Tissue Products
/PRNewswire/ -- StimLabs is announcing two revolutionary products in regenerative medicine. Revita, the first full thickness placental membrane allograft in a...
